ANI Pharmaceuticals: A Strong Buy for Rare Disease Growth and Consistent Earnings Beats

ANI Pharmaceuticals is a profitable, fast-growing biopharmaceutical company focused on rare diseases and underserved patients. The company has accelerated its growth by reinvesting profits from its rare disease, generic, and branded drug sales into research and development. ANI has a record of beating estimates and is a strong buy due to its rare disease growth potential.